Cartesian Looks To Chart The Way For CAR-T In Autoimmune Disease

A Phase IIb trial testing Cartesian’s autologous mRNA-engineered CAR-T therapy for the treatment of generalized myasthenia gravis (MG) met the primary endpoint.

autoimmune disease
Cartesian announced clinical trial data for a CAR-T in autoimmune disease. • Source: Shutterstock

Cartesian Therapeutics, Inc. has positive data from a Phase IIb trial testing Descartes-08, an autologous mRNA-engineered chimeric antigen receptor T-cell (CAR-T) therapy directed against the B-cell maturation antigen (BCMA) in patients with generalized myasthenia gravis (MG), positioning the company at the forefront of development of CAR-T therapeutics for autoimmune disease.

Key Takeaways
  • A Phase IIb trial testing Descartes-08, an autologous mRNA-engineered CAR-T therapy in patients with generalized myasthenia gravis (MG), was positive.

The trial represents the first placebo-controlled study of a CAR-T cell therapy in autoimmune disease to the best of Cartesian’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immunological

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By 

The Belgian drugmaker is boosting its biologics capacity over the pond.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from Therapy Areas

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By 

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.